## United States of America

### Tuberculosis profile

#### Population 2018

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>9.8 (8.4–11)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.5 (0.42–0.6)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence*</td>
<td>0.21 (0.16–0.27)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.58 (0.57–0.59)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.077 (0.05–0.11)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 1.5% (1.2–1.9)
- Previously treated cases: 7.4% (4.5–12)

#### TB case notifications, 2018

- Total new and relapse: 8,561
  - % tested with rapid diagnostics at time of diagnosis: 87%
  - % with known HIV status: 79%
  - % pulmonary: 86%
  - % children aged 0-14 years: 37%
  - % men: 59%

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)
- TB patients facing catastrophic total costs: 7% (6–8)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 1%
- % with known HIV status who are HIV-positive: 381 5%
  - on antiretroviral therapy: 90%
- % of bacteriologically confirmed TB cases tested for rifampicin resistance*<sup>**</sup>: 90%
  - New cases: 90%
  - Previously treated cases: 81%

#### Drug-resistant TB care, 2018

- % of laboratory-confirmed cases*<sup>**</sup> tested for rifampicin resistance<sup>***</sup>: 90%
  - MDR/RR-TB: 111, XDR-TB: 1
- % of bacteriologically confirmed TB cases tested for resistance to second-line drugs: 87%
  - MDR/RR-TB: 106, XDR-TB: 1

#### Treatment success rate and cohort size

- New and relapse cases registered in 2017: 77% 8,536
- Previously treated cases, excluding relapse, registered in 2017: 76% 401
- HIV-positive TB cases registered in 2017: 68% 403
- MDR-RR-TB cases started on second-line treatment in 2016: 69% 111
- XDR-TB cases started on second-line treatment in 2016: 100% 1

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 87%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 100%

#### TB financing, 2019

- National TB budget (US$ millions): 135

* Ranges represent uncertainty intervals
*<sup>**</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
**<sup>***</sup> Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-04-11

Data: [www.who.int/tb/data](http://www.who.int/tb/data)